Understanding the Role of T Cells in CNS Homeostasis

Trends in Immunology

Volumn 37, Issue 2, 2016, Pages 154-165

  Ellwardt, Erik ^a   Walsh, James T ^b   Kipnis, Jonathan ^a,b   Zipp, Frauke ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BEHAVIOR; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CONVALESCENCE; ENCEPHALITIS; HUMAN; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MENINGITIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TRAUMATIC BRAIN INJURY; ANIMAL; HOMEOSTASIS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; NEUROGENIC INFLAMMATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; HOMEOSTASIS; HUMANS; LYMPHOCYTE DEPLETION; NEUROGENIC INFLAMMATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84983130412     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.12.008     Document Type: Review

References (114)

1. 1 Turrigiano, G., Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement. Annu. Rev. Neurosci. 34 (2011), 89–103.
2. 2 Turrigiano, G., Homeostatic synaptic plasticity: local and global mechanisms for stabilizing neuronal function. Cold Spring Harb. Perspect. Biol., 4, 2012, a005736.
3. 3 Medawar, P.B., Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29 (1948), 58–69.
4. 4 Tzartos, J.S., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172 (2008), 146–155.
5. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192 (2000), 393–404.
6. 6 Liblau, R.S., et al. Neurons as targets for T cells in the nervous system. Trends Neurosci. 36 (2013), 315–324.
7. 7 Ellwardt, E., Zipp, F., Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp. Neurol. 262 (2014), 8–17.
8. + T cells present in the human brain. Acta Neuropathol. 126 (2013), 525–535.
9. 9 Zipp, F., Aktas, O., The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 29 (2006), 518–527.
10. 10 Aspelund, A., et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212 (2015), 991–999.
11. 11 Louveau, A., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523 (2015), 337–341.
12. 12 Engelhardt, B., Ransohoff, R.M., The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26 (2005), 485–495.
13. + T cell compartmentalization. Brain 132 (2009), 1247–1258.
14. + T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 8389–8394.
15. + regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 15620–15625.
16. 16 Kipnis, J., et al. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J. Neurosci. 21 (2001), 4564–4571.
17. 17 Kipnis, J., et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. U.S.A. 97 (2000), 7446–7451.
18. 18 Xie, L., et al. Cerebral regulatory T cells restrain microglia/macrophage-mediated inflammatory responses via IL-10. Eur. J. Immunol. 45 (2015), 180–191.
19. 19 Kunis, G., et al. Immunization with a myelin-derived antigen activates the brain's choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS. J. Neurosci. 35 (2015), 6381–6393.
20. 20 CAMMS223 Trial Investigators, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359 (2008), 1786–1801.
21. 21 Jones, J.L., et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133 (2010), 2232–2247.
22. 22 Steinman, L., Role reversal: infiltrating T cells protect the brain. J. Clin. Invest. 125 (2015), 493–544.
23. 23 Yau, S.Y., et al. Involvement of adult hippocampal neurogenesis in learning and forgetting. Neural Plast., 2015, 2015, 717958.
24. 24 Kempermann, G., et al. More hippocampal neurons in adult mice living in an enriched environment. Nature 386 (1997), 493–495.
25. 25 Ziv, Y., et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 9 (2006), 268–275.
26. 26 Wolf, S.A., et al. CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis. J. Immunol. 182 (2009), 3979–3984.
27. 27 Kipnis, J., et al. T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 8180–8815.
28. + cells. J. Neurobiol. 66 (2006), 552–563.
29. + T cells revert the impaired emotional behavior of immunocompromised RAG-1-deficient mice. Transl. Psychiatry, 3, 2013, e280.
30. 30 Dunn, A.J., et al. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci. Biobehav. Rev. 29 (2005), 891–909.
31. 31 Kappos, L., et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 10 (2011), 745–758.
32. 32 Bloomgren, G., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366 (2012), 1870–1880.
33. 33 Ascioglu, S., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis. 34 (2002), 7–14.
34. 34 Perreau, M., et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210 (2013), 143–156.
35. 35 Marques, C.P., et al. Prolonged microglial cell activation and lymphocyte infiltration following experimental herpes encephalitis. J. Immunol. 181 (2008), 6417–6426.
36. 36 Mutnal, M.B., et al. Memory T cells persisting in the brain following MCMV infection induce long-term microglial activation via interferon-gamma. J. Neurovirol. 17 (2011), 424–437.
37. 37 Verjans, G.M., et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 3496–3501.
38. + T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 18 (2003), 593–603.
39. 39 Stohlman, S.A., et al. CD4 T cells contribute to virus control and pathology following central nervous system infection with neurotropic mouse hepatitis virus. J. Virol. 82 (2008), 2130–2139.
40. 40 Tishon, A., et al. CD4 T cell control primary measles virus infection of the CNS: regulation is dependent on combined activity with either CD8 T cells or with B cells: CD4, CD8 or B cells alone are ineffective. Virology 347 (2006), 234–245.
41. + T lymphocytes control murine cytomegalovirus replication in the central nervous system of newborn animals. J. Immunol. 181 (2008), 2111–2123.
42. 42 Wakim, L.M., et al. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 17872–17879.
43. + T cells responding to infection. Nat. Immunol. 16 (2015), 406–414.
44. 44 Wakim, L.M., et al. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J. Immunol. 189 (2012), 3462–3471.
45. 45 Hoffmann, O., et al. Lymphocytes modulate innate immune responses and neuronal damage in experimental meningitis. Infect. Immun. 83 (2015), 259–267.
46. 46 Herz, J., et al. Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells. J. Exp. Med. 212 (2015), 1153–1169.
47. 47 Kulcsar, K.A., et al. Interleukin 10 modulation of pathogenic Th17 cells during fatal alphavirus encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 16053–16058.
48. 48 Hoffmann, O., et al. TRAIL limits excessive host immune responses in bacterial meningitis. J. Clin. Invest. 117 (2007), 2004–2013.
49. 49 Luchtman, D.W., et al. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments. Cytokine Growth Factor Rev. 25 (2014), 403–413.
50. 50 Lock, C., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002), 500–5008.
51. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004), 971–979.
52. 52 Huan, J., et al. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81 (2005), 45–52.
53. high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123 (2008), 79–89.
54. 54 Dalla Libera, D., et al. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS ONE, 6, 2011, e21386.
55. + regulatory T cells in human autoimmune disease. Nat. Med. 17 (2011), 673–675.
56. 56 Dhainaut, M., et al. Thymus-derived regulatory T cells restrain pro-inflammatory Th1 responses by downregulating CD70 on dendritic cells. EMBO J. 34 (2015), 1336–1348.
57. + regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 183 (2009), 7602–7610.
58. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110 (2007), 1225–1232.
59. 59 Muls, N., et al. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients. PLoS ONE, 9, 2014, e113025.
60. 60 Mehling, M., et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71 (2008), 1261–1267.
61. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 10 (2010), 490–500.
62. 62 Joller, N., et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40 (2014), 569–581.
63. 63 Lozano, E., et al. The TIGIT/CD226 axis regulates human T cell function. J. Immunol. 188 (2012), 3869–3875.
64. 64 Yu, X., et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10 (2009), 48–57.
65. 65 Stumhofer, J.S., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8 (2007), 1363–1371.
66. 66 Fitzgerald, D.C., et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8 (2007), 1372–1379.
67. 67 Walsh, J.T., et al. T cells in the central nervous system: messengers of destruction or purveyors of protection?. Immunology 141 (2014), 340–344.
68. 68 Yan, Z., et al. Extracellular redox modulation by regulatory T cells. Nat. Chem. Biol. 5 (2009), 721–723.
69. 69 Garg, S.K., et al. IFN-gamma and IL-4 differentially shape metabolic responses and neuroprotective phenotype of astrocytes. J. Neurochem. 108 (2009), 1155–1166.
70. 70 Hauben, E., et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 108 (2001), 591–599.
71. 71 Hauben, E., et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet 355 (2000), 286–287.
72. 72 Moalem, G., et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5 (1999), 49–55.
73. 73 Shrestha, R., et al. Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways. Neuropharmacology 76 (2014), 184–193.
74. 74 Kerschensteiner, M., et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. J. Exp. Med. 189 (1999), 865–870.
75. 75 Walsh, J.T., et al. Regulatory T cells in central nervous system injury: a double-edged sword. J. Immunol. 193 (2014), 5013–5022.
76. + T cells protect injured CNS neurons via IL-4. J. Clin. Invest. 125 (2015), 699–714.
77. + microglia phenotype and recruits macrophages to the inflammatory CNS: consequences of age-related deficits in IL-4Ralpha after traumatic spinal cord injury. J. Neurosci. 34 (2014), 8904–8917.
78. 78 Zhao, X., et al. Neuronal interleukin-4 as a modulator of microglial pathways and ischemic brain damage. J. Neurosci. 35 (2015), 11281–11291.
79. 79 Baruch, K., et al. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 2264–2269.
80. 80 Kleinschnitz, C., et al. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood 115 (2010), 3835–3842.
81. 81 Shichita, T., et al. Pivotal role of cerebral interleukin-17-producing gamma delta T cells in the delayed phase of ischemic brain injury. Nat. Med. 15 (2009), 946–950.
82. 82 Gelderblom, M., et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood 120 (2012), 3793–3802.
83. 83 Liesz, A., et al. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 134 (2011), 704–720.
84. 84 Liesz, A., et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med. 15 (2009), 192–199.
85. 85 Lin, L., et al. IL-10 protects neurites in oxygen-glucose-deprived cortical neurons through the PI3K/Akt pathway. PLoS ONE, 10, 2015, e0136959.
86. 86 Stubbe, T., et al. Regulatory T cells accumulate and proliferate in the ischemic hemisphere for up to 30 days after MCAO. J. Cereb. Blood Flow Metab. 33 (2013), 37–47.
87. 87 Wang, M., et al. Albumin induces neuroprotection against ischemic stroke by altering Toll-like receptor 4 and regulatory T cells in mice. CNS Neurol. Disord. Drug Targets 12 (2013), 220–227.
88. 88 Li, P., et al. Adoptive regulatory T-cell therapy preserves systemic immune homeostasis after cerebral ischemia. Stroke 44 (2013), 3509–3515.
89. 89 Li, P., et al. Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke. Stroke 45 (2014), 857–864.
90. 90 Ishibashi, S., et al. Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J. Cereb. Blood Flow Metab. 29 (2009), 606–620.
91. 91 Heneka, M.T., et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14 (2015), 388–405.
92. + T regulatory cells in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 21 (2010), 927–938.
93. + regulatory T cells mitigates Alzheimer's disease pathology. Nat. Commun., 6, 2015, 7967.
94. 94 Chakrabarty, P., et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85 (2015), 519–533.
95. 95 Yang, H., et al. Systemic transplantation of human umbilical cord derived mesenchymal stem cells-educated T regulatory cells improved the impaired cognition in AbetaPPswe/PS1dE9 transgenic mice. PLoS ONE, 8, 2013, e69129.
96. 96 Browne, T.C., et al. IFN-gamma production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J. Immunol. 190 (2013), 2241–2251.
97. 97 Monsonego, A., et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112 (2003), 415–422.
98. 98 Chiu, I.M., et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 17913–17918.
99. 99 Zhao, W., et al. Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol. Dis. 48 (2012), 418–428.
100. 100 Beers, D.R., et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134 (2011), 1293–1314.
101. + T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 15558–15563.
102. 102 Bowerman, M., et al. Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. Front. Cell Neurosci., 7, 2013, 214.
103. 103 O'Rourke, J.G., et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 88 (2015), 892–901.
104. 104 Peters, O.M., et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 88 (2015), 902–909.
105. 105 Meininger, V., et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 10 (2009), 378–383.
106. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119 (2009), 182–192.
107. 107 Benner, E.J., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 9435–9440.
108. 108 Lacan, G., et al. Bacillus Calmette–Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. Res. 91 (2013), 1292–1302.
109. 109 Lindstrom, V., et al. Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Immunotherapy 6 (2014), 141–153.
110. 110 Egli, A., et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 199 (2009), 837–846.
111. 111 Tan, I.L., et al. Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology 79 (2012), 2125–2132.
112. 112 Whitley, R.J., Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 71 (2006), 141–148.
113. 113 Schmidt, M., et al. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study. Clin. Infect. Dis. 57 (2013), 1535–1541.
114. 114 Perfect, J.R., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50 (2010), 291–322.